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ABSTRACT
Expression of hTERT is the major limiting factor for
telomerase activity. We previously showed that
methylation of the hTERT promoter is necessary
for its transcription and that CTCF can repress
hTERT transcription by binding to the first exon. In
this study, we used electrophoretic mobility shift
assay (EMSA) and chromatin immunoprecipitation
(ChIP) to show that CTCF does not bind the
methylated first exon of hTERT. Treatment of
telomerase-positive cells with 5-azadC led to a
strong demethylation of hTERT 50-regulatory
region, reactivation of CTCF binding and down-
regulation of hTERT. Although complete hTERT
promoter methylation was associated with full
transcriptional repression, detailed mapping
showed that, in telomerase-positive cells, not all
the CpG sites were methylated, especially in the
promoter region. Using a methylation cassette
assay, selective demethylation of 110bp within the
core promoter significantly increased hTERT tran-
scriptional activity. This study underlines the dual
role of DNA methylation in hTERT transcriptional
regulation. In our model, hTERT methylation pre-
vents binding of the CTCF repressor, but partial
hypomethylation of the core promoter is necessary
for hTERT expression.
INTRODUCTION
Telomeres are nucleoprotein complexes that ‘cap’ and
stabilize the termini of linear chromosomes. They are also
involved in chromosome replication, maintenance of
nuclear architecture, chromosome stability, gene expres-
sion, aging and cell division (1,2). In normal cells, each
division is associated with the loss of 50–100 base pairs of
telomere length. This shortening of the telomeres acts
as a mitotic counter and limits life span. Telomerase,
a complex consisting of a reverse transcriptase bound to
its own RNA template, allows the maintenance of the
telomere length (3). In most somatic cells, telomerase
activity is not detectable (4). In contrast, telomerase is
expressed in highly proliferative cells, such as germ
cells and stem cells, and in the cells of about 85% of
cancers (5). In vitro, two components are absolutely
essential for telomerase activity: the catalytic subunit,
hTERT, containing the reverse transcriptase activity,
and the RNA component, hTERC, containing a com-
plementary template for the telomeric DNA sequence
(TTAGGG) (6,7).
Following the characterization of the genomic sequence
of hTERT and the elucidation of the organization of
the gene (8–11), many studies have shown that expression
of hTERT represents the limiting factor for telomerase
activity, and that the regulation of hTERT expression
occurs primarily at the transcriptional level. Transient
transfection experiments have identiﬁed a minimal
promoter encompassing the 283bp region upstream
of the ATG initiation codon (9–11). The 50-hTERT
regulatory region contains numerous binding sites for
transcription factors. Activators of hTERT transcription
include c-Myc, Sp1, hALP, Hif-1, Mbi-1, USF1/2
and estrogen response element. Repressors for hTERT
have also been identiﬁed and include the tumor suppres-
sor protein p53, Mad1, myeloid-speciﬁc zinc ﬁnger
protein 2 (MZF-2), TGF-b, Wilms’ Tumor 1 (WT1) and
CTCF. (12–20). Recently, Horikawa et al. described an
E-box binding sequence located upstream of the
transcriptional start site, as inhibitor of hTERT but
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TERT in human and mouse (21). We previously showed
that 50 exonic sequences might be involved in the
regulation of the hTERT gene through an inhibitory
eﬀect on transcriptional activity of the minimal hTERT
promoter (22). Moreover, this region inserted immediately
downstream of CMV and CDKN2A promoters
repressed their activity in normal, immortalized
and cancer cells. We observed that the 11-zinc ﬁnger
factor CTCF binds this region in telomerase-negative
cells, but not in telomerase-positive cells (18). Since
CTCF represses transcriptional activity when it binds
DNA downstream of transcriptional start sites (23,24),
these ﬁndings suggest that CTCF might function as
a transcriptional repressor for hTERT in normal cells.
However, the mechanisms that might prevent CTCF from
binding to the hTERT gene in telomerase-positive cells
have not been determined. Therefore, it is essential to
note that the identiﬁcation of these activators and
repressors of hTERT do not take in account the
methylation proﬁle of the hTERT promoter described in
numerous studies (25–27).
The fact that the hTERT promoter is located within
a CpG island suggests that transcription of the gene
might be regulated by DNA methylation. Previous
studies showed that the hTERT promoter is hypermethy-
lated in most telomerase-positive tumors and hypomethy-
lated in telomerase-negative normal tissues (25–27).
These observations contrast with the general
association between promoter methylation and gene
silencing (28), which prompted us to study how DNA
methylation of the hTERT promoter can lead to
its expression.
To this end, we initiated a detailed evaluation of
the methylation pattern of each CpG site in the
areas that appear to contribute to the transcriptional
regulation of the hTERT gene. Based on our previous
analyses (22), two regions of the hTERT CpG
island seemed essential: one is the core promoter that is
necessary to its expression; the other is the 50 exonic
region where the CTCF repressor binds. The hTERT
region at  441 to  218 from the ATG translational
start site examined in our previous studies was located
immediately upstream of the regions we considered now
as essential (29).
Although the ﬁrst two exons play a role in the
repression of the hTERT transcription by CTCF, which
binds to two sites, one in the ﬁrst exon and the other at
the beginning of the second (18); in the present study,
only the eﬀect of CTCF on the ﬁrst exon was investigated.
The presence of an intron between these two CTCF sites
complicate the analyses since, in transient transfections,
splicing of this intron is only partial.
In the present report, we tested the hypothesis that
hTERT methylation prevents binding of CTCF inhibitor
and that a partial methylation of the hTERT promoter
region can result in some level of transcriptional activity.
The results have allowed us to identify an unexpected dual
role for DNA methylation in the transcriptional regula-
tion of the hTERT promoter.
MATERIALS AND METHODS
Cell culture
The human tumor cell lines HeLa (cervical adenocarci-
noma), SW480 (colorectal adenocarcinoma) and normal
BJ ﬁbroblasts were obtained from the ATCC. All these
cells were grown in the medium recommended by the
ATCC. The HLF/hTERT cells were kindly provided by
Dr. Joachim Lingner (ISREC, Epalinges, Switzerland),
and were cultured in DMEM supplemented with 10%
heat inactivated fetal bovine serum (Invitrogen, Basel,
Switzerland). HeLa and SW480 cell lines are telomerase
positive, whereas BJ is telomerase negative. HLF/hTERT
cells, obtained through stable transfection of HLF cells
with an MSCV-hTERT retrovirus, constitutively express
hTERT and have high telomerase activity.
Tissue samples
Tumor tissues (breast, bladder and cervix) were obtained
from the Tissue Bank of the Institute of Pathology of
Lausanne. Microdissection and DNA extraction were
performed as described previously (30). Brieﬂy, frozen
tissue sections (7-mm thickness) were stained with toluidin
blue. Then, normal cells were removed by scratching.
Veriﬁcation that the remaining cells were indeed tumor
was performed before the cells were harvested.
Plasmid construction
For stable transfection, hTERT sequences and ﬁreﬂy
luciferase gene were extracted from the pTERT-297/ex2
vector, containing the hTERT minimal promoter and the
1071bp downstream of the ATG (22), by digestion with
Asp718I and BamHI. Then, this fragment was cloned
into the pcDNA5/FRT vector (Invitrogen), previously
deleted of the CMV promoter, in order to create the
pTERT-297/ex2/FRT that is used in stable transfection
experiments with or without in vitro methylation of all the
CpG sites with the SssI methylase (Promega, Madison,
WI, USA). Full methylation was conﬁrmed by digestion
with MspI (Promega, Madison, WI) and HpaII
(Amersham Biosciences Buckinghamshire, England)
restriction enzymes.
pCpG-LacZ, a CpG-free vector (InvivoGen, San Diego,
CA, USA), was used to study the eﬀect of hTERT
methylation on transcriptional activity. hTERT minimal
promoter and exon 1 were generated by PCR, using
primers containing either the SdaI or the XbaI sites. These
fragments were cloned into pCpG-LacZ to produce
pCpG-Tm (hTERT promoter) and pCpG-Tmex1
(hTERT promoter and the ﬁrst 80bp of the exon 1).
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed as previously described (18).
Then, puriﬁed DNA was analyzed by PCR
with speciﬁc primers for the co-ampliﬁcation of the ﬁrst
exon of the hTERT gene to generate a 171-bp
fragment (TERT-FW 50-CTGCTGCGCACGTGGGAA
GCC-30 and TERT-REV 50-GTCCCCGCGCTGCA
CCAGCC-30) or the H19 gene as a 149-bp control (H19-
FW 50-CACCGCCTGGATGGCACGGAATTG-30 and
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Ampliﬁcation was performed with the following PCR
conditions: 948C for 30s, 628C for 45s and 728C for 60s.
The cycle number and the amount of template were varied
to ensure that results were within the linear range of the
PCR. PCR products were analyzed on 2% agarose gel.
ChIP experiments were carried out in triplicate to ensure
reproducibility.
DNA methylation analysis
DNA was extracted from culture cells and modiﬁed
with sodium bisulﬁte, as previously described (31).
After bisulﬁte modiﬁcation, PCR were performed with
primers speciﬁcally designed to ampliﬁy bisulﬁte-modiﬁed
DNA sequence of the promoter and ﬁrst exon of hTERT
50-CTACCCCTTCACCTTCCAA-30 and 50-GTTAGTTT
TGGGGTTTTAGG-30. The ampliﬁed region corre-
sponded to nucleotide positions 3791-4105 of the
unmodiﬁed hTERT gene sequence (GenBank
AF097365). Ampliﬁcation was performed using the
master mix (Promega), with the following PCR condi-
tions: 40 cycles of 948C for 30s, 578C for 45s and 728C for
50s. PCR products were cloned into the pGEM-T vector
using the pGEM-T vector system II (Promega). DNA
extracted from bacterial clones (QIAprep Spin Miniprep
Kit, Qiagen) was analyzed by sequencing with the M13
forward primer (50-GTAAAACGACGGCCAG-30), using
a Big Dye Terminator Cycle Sequencing Kit, and an
ABI Prism 3100 sequencer (Applied Biosystems, Foster
City, CA).
To verify the methylation status of the hTERT
stable transfectant, DNA from cells were extracted
with the DNeasy extraction kit (Qiagen) and analyzed
by MS-SSCA (Methylation-Sensitive Single Strand
Conformation Analysis) (31). The forward Primer used
was speciﬁc to the plasmid sequence (50-TGTATGA
AGAATTTGTTTAGGGTTA-30), and the reverse
primer was located within the second exon of hTERT
(50-AACCACCAACTCCTTCAAA-30).
Electrophoretic mobility shiftassay(EMSA)
The F1 fragment, which contains part of the ﬁrst exon of
hTERT, was synthesized by PCR using the plasmid
pTERT-297/ex2 as template, previously sequenced and
published (22) and with the following primers previously
used (18): 50-CCTGCTGCGCACGTGGGAAGCC-30
and 50-GGCAGCACCTCGCGGTAGTGG-30. Puriﬁed
fragments were veriﬁed by sequencing. Five mg were
methylated with 2 units/mg SssI methyltransferase in the
presence of 180mM S-adenosyl-L-methionine for 16h at
378C. Following termination of methylation reaction
by heating at 658C for 15min, the methylation status of
plasmid constructs was analyzed by digesting overnight
with an excess amount of BstUI. EMSA was then
performed as previously described (18).
Transfection and b-galactosidaseassays
Stable transfection experiments were performed with the
Flp-In system, allowing integration of the gene of interest,
always at the same site, in the genome of a mammalian
cell, following the manufacturers0 recommendations
(Invitrogen). A HeLa Flp-In host cell line containing a
single FRT site was created with this system. Positive
clones were selected using 500mg/ml of Zeocin antibiotic.
The vector containing the gene of interest was integrated
into the genome via Flp-recombinase-mediated DNA
recombination at the FRT site. Integration confers
hygromycin resistance and Zeocin sensitivity. Cells were
selected with 600mg/ml of Hygromycin antibiotic.
Transient transfection assays were performed with cells
seeded at a concentration of either 200000/3.8cm
2 for
HeLa and SW480, or 50000 cells/3.8cm
2 for BJ. Cells
were then cultured overnight. Transient transfection of
reporter plasmids (0.75mg/well) was carried out in
triplicate using JetPEI Cationic Polymer Transfection
reagent (4ml/well) (Polyplus-transfection, Illkirch,
France). All experiments were performed at least twice
and in triplicate. Analysis of LacZ reporter plasmids was
performed with a b-galactosidase assay. Brieﬂy, protein
was extracted from cells using 500ml of the 5X passive
lysis buﬀer (Promega). In a 96-wellplate, 50ml of cell lysate
was analyzed with 100ml of the b -galactosidase substrate
buﬀer (NaH2PO4 0.2M, pH 8, b-mercaptoethanol 0.1M,
MgCl2 2mM, ONPG 1.33mg/ml). The kinetics of the
b-galactosidase activity was followed with a colorimeter at
414nm during 15min. The kinetics deﬁned a linear curve,
and the mean was calculated with values taken at ﬁxed
time points. b-galactosidase activity of the diﬀerent
constructs was compared to the level of the pCpG-LacZ
vector containing the synthetic LacZCpG gene under
the control of a mammalian promoter (combination of the
CMV enhancer, the human elongation factor 1 alpha core
promoter and 50UTR containing a synthetic intron) and to
the level of the pCpG-basic vector, corresponding to that
of the pCpG-LacZ vector without its promoter region.
Methylation cassette assay
A methylation cassette assay was used to determine
the eﬀect of hypomethylation of a speciﬁc regulatory
region on hTERT transcription. Two restriction sites
were introduced by site-directed mutagenesis using
the QuickChange XL Site-Directed Mutagenesis Kit
(Stratagene, CA, USA) in pCpG constructs. The mut1
primers set (FW-mut1 50-ACCTTCCAGCTCCGGATCC
TCCGCGCGGAC-30 and REV-mut1 50-GTCCGCGC
GGAGGATCCGGAGCTGGAAGGT-30) created the
upstream site BamHI (indicated in bold) and the mut2
primers set (FW-mut2 50-CCGCCCTCTCCTCGACGG
CGCGAGTTTCAGG-30 and REV-mut2 50-CCTGAAA
CTCGCGCCGTCGAGGAGAGGGCGG-30) created the
downstream site TaqI (indicated in bold). The generated
plasmids, pCpG-Tm  (containing the hTERT minimal
promoter) and pCpG-Tmex1  (containing the hTERT
minimal promoter and the ﬁrst 80bp of exon 1), were
methylated in vitro with the SssI methylase following the
manufacturers instructions (Promega). The methylated
and unmethylated cassette BamHI-TaqI 110bp fragment
( 183 to  74bp of the hTERT sequence) were extracted
through enzymatic digestion and ligated back into the
methylated or unmethylated vector, using the Ligafast
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ligation reaction was assessed by analysis of an aliquot of
the ligation reaction mixture on a 1% agarose gel. The
methylated, unmethylated and partially methylated con-
structs were conﬁrmed by digestion with HpaII restriction
enzyme. The remainder of the ligation reaction mixtures
was then transfected into HeLa cells. b-galactosidase
activities were measured as described.
5-azadCtreatment
Treatment with the demethylating agent, 50-aza-20-deoxy-
cytidine (5-azadC), was performed on HeLa and SW480
cell lines. Cells were treated 24h after seeding with 3mMo f
5-azadC (Flucka, Buchs, Switzerland) in 48-h intervals
and for four passages. Cells were then collected and
treated for ChIP or used for DNA and RNA extractions
(as described below).
RNA extraction, reverse transcription and real-time PCR
RNA was extracted from cells before and after 5-azadC
treatment, using the TRIzol LS Reagent (Invitrogen).
RNA was then converted to cDNA using random primers
and Superscript III reverse transcriptase (Invitrogen,
Carlsbad, CA). Real-time PCR analysis was preformed
using the TaqMan Universal PCR Master Mix (Applied
Biosystems, Foster city, CA) and using the Applied
Biosystems 7900HT Real-Time PCR system. CTCF
expression was determined using the following primers
and probe: 50-TGACACAGTCATAGCCCGAAAA-30
(FW), 50-TGCCTTGCTCAATATAGGAATGC-30
(REV) and 6FAM-TGATTTGGGTGTCCACTTGCG
AAAGC-MGB (probe). Human Glycerhaldehyde-
3-phosphate dehydrogenase (hGAPDH: 99999905) and
human Telomerase Reverse transcriptase (hTERT:
00162669) primers/probe mixtures were purchased as
Predevelopped Assay (Applied Biosystems, Foster
city, CA).
RESULTS
Interaction of CTCF withthe first exon ofhTERT is
methylation dependent
To evaluate binding of CTCF to sequences within the ﬁrst
exon of hTERT, ChIP assays were performed on
telomerase-positive tumor cell lines (HeLa, SW480),
normal telomerase-negative cells (BJ) and telomerase-
positive cells immortalized by hTERT transfection
(HLF/hTERT). CTCF binding to the ICR of H19 gene
was used as a positive control for the eﬃciency of the
experimental protocol. PCR reactions were performed
under conditions in which the negative control samples
(no antibody) always showed negligible levels of back-
ground ampliﬁcation (data not shown). ChIP experiments
were performed in a way that the positive control, H19,
was coampliﬁed with the hTERT exon 1 in a single
reaction and PCR fragments were resolved on the same
gel. Results show that CTCF bound to the ﬁrst exon of the
endogenous hTERT gene of hTERT-negative BJ
and HLF/hTERT cells but not of the tumor cell lines
tested (Figure 1A). These results support our previous
data (18) and are more convincing because positive
controls and experimental fragments were ampliﬁed in
the same reaction.
As methylation of CpG dinucleotides within the CTCF
recognition sequence can inﬂuence its binding (32), we
examined the methylation status of CpG sites within the
hTERT minimal promoter and the ﬁrst exon sequences
from  200 to þ100 from the ATG using bisulﬁte
modiﬁcation, PCR ampliﬁcation, and subsequent cloning
and sequencing of the PCR products. Clones from two
tumor cell lines, HeLa and SW480, two normal cell lines,
BJ and HLF/hTERT, as well as tumor tissues from breast,
bladder and cervical cancer were sequenced and are
presented in Figure 2. In tumor tissues and tumor cell
lines, almost all CpGs between  100 and þ100, including
the CTCF binding site (Region B) were methylated (75 to
100% methylated). By comparison, most of the CpGs
from approximately  165 to  100 (Region A) were
unmethylated (0 to 55% methylated). In BJ and HLF/
hTERT, very few CpGs in the entire region were
methylated (3 to 23%). These ﬁndings suggested that
methylation of CpGs in Region B might inhibit
CTCF binding while leaving unexplained the selective
hypomethylation of Region A.
To test whether methylation might interfere with CTCF
binding, we used SssI methylase to modify a PCR
fragment encompassing the ﬁrst exon of the hTERT
gene, previously derscribed to be bound by CTCF (18),
and compared the native (F1) and modiﬁed sequences
(F1-met) for their ability to bind CTCF in EMSAs. These
studies revealed a marked preference of CTCF for the
unmethylated site (Figures 1B and C).
We also tested the eﬀect of CpG methylation on the
aﬃnity of CTCF binding in vivo. HeLa cells were stably
transfected with an hTERT construct, pTERT –297/ex2/
FRT (Figure 1D) that was methylated in vitro before
transfection. Genomic DNA of stable transfectants was
extracted after 30 population doublings (PD) and the
methylation status was analyzed by Methylation-Sensitive
Single-Strand Conformation Analysis (MS-SSCA). To
diﬀerentiate endogenous hTERT gene sequences from the
transfected sequence, we used a speciﬁc forward primer
located in the reporter vector (Figure 1D). The transfected
hTERT sequence remained methylated even after 30 PDs,
whereas the unmethylated control transfectant stayed
unmethylated (Figure 1E). ChIP assays were performed
on methylated and unmethylated stable transfectants.
CTCF bound to the hTERT exon1 region of the
vector sequences only when this region was unmethylated
(Figure 1F). Taken together, these results indicated that
methylation of the ﬁrst exon of hTERT prevented binding
of CTCF both in vitro and in vivo.
CTCF binding isrestored after treatment with5-azadC
As was shown in previous studies (33–35), treatment of
telomerase-positive cells with the demethylating agent
5-azadC inhibits hTERT transcription and reduces telo-
merase activity. We hypothesize that demethylation of the
ﬁrst exon of hTERT restores CTCF binding. To test this
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5-azadC for 4 weeks. Methylation of hTERT as deter-
mined by bisulﬁte sequencing showed that CpG methyla-
tion in Region B was reduced from that in untreated cells
(54 and 64% methylated after 5azadC treatment versus 93
and 90% methylated in untreated HeLa and SW480 cells,
respectively) (Figure 2 and 3A). ChIP analyses revealed
signiﬁcant CTCF binding to hTERT ﬁrst exon sequences
from treated cells (Figure 3B). In addition, real-time PCR
analyses of hCTCF mRNA levels showed no signiﬁcant
diﬀerences before and after 5azadC treatment. In contrast,
the hTERT mRNA level, which is high in HeLa and
SW480 before 5azadC treatment, cannot be detected after
5azadC treatment (Figure 3C).
Total methylation of hTERT inhibits transcriptional
activity: aregion ofthe hTERTminimal promoter must be
hypomethylated to allow its transcriptional activity
To evaluate the importance of methylation for hTERT
activation, HeLa cells were transiently transfected with
CpG-free plasmids containing a hTERT promoter that
was previously methylated in vitro. The hTERT minimal
promoter did not show any activity if all the CpG sites
were methylated (Figure 4A). Likewise, no transcriptional
activity was observed in a construct with methylated
promoter and the ﬁrst exon of hTERT. These results
showed that transcription of hTERT was completely
repressed by full methylation of the promoter.
Sequencing of bisulﬁte-modiﬁed DNA from telomerase-
positive tumor cell lines (HeLa and SW480) and tumor
tissues (breast, bladder and cervix) showed partial
demethylation of the promoter, between  160 to  80bp
(Figure 2, Region A). A recent study has also described
partial methylation of the promoter region in telomerase-
positive cell lines (35). This hypomethylation, just
upstream of the transcriptional start sites, might permit
the low transcriptional activity of the hTERT promoter
observed in tumor cells (36,37). To test the role of
methylation of this region in the regulation of hTERT
transcriptional activity, we performed a methylation
cassette assay (38). A b-galactosidase reporter plasmid
was generated, containing a cassette with sequences from
 183 to  73bp, encompassing 12 CpG sites and
representing the region A described in Figure 2. The
methylated or unmethylated cassette was excised and
ligated back into the vector, which was then transfected
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Figure 1. Methylation-sensitive binding of CTCF to the ﬁrst exon of hTERT. (A) In vivo binding of CTCF to the ﬁrst exon of hTERT in telomerase-
positive and negative cell lines was analyzed by ChIP assay using anti-CTCF antibody. PCR coampliﬁcation of the test fragments (hTERT and H19)
using as template DNA input fraction and DNA recovered from immunoprecipitated fractions bound by the anti-CTCF antibody. (B) 50-end-labeled
control (F1) and SssI methylase-treated (F1-met) fragments were digested with methylation-sensitive BstUI and analyzed on polyacrylamide gels to
verify eﬃciency of in vitro methylation. (C) Control unmethylated (F1) or SssI-methylated (F1-met) fragments were analyzed by gel-shift assay
(EMSA). F, free probe; B, CTCF-bound probe. (D) Representation of the hTERT sequence cloned into the pTERT-297/ex2/FRT. Arrows represent
the localization of the primers used for hTERT methylation analysis of stable transfectant. (E) The methylation status of the stable transfectants was
veriﬁed by MS-SSCA. Unmethylated and fully methylated controls were obtained from plasmids used for stable transfection. UT and MT represent,
respectively, the unmethylated and methylated plasmids stably transfected into HeLa cells, and after 30 population doublings. (F) Binding of CTCF
to the ﬁrst exon of hTERT in stably transfected cell line was analyzed by ChIP assay using anti-CTCF antibody.
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activity of the hTERT promoter to the background levels,
a result similar to that obtained with the fully methylated
promoter (Figure 4B). In contrast, the unmethylated
cassette, ligated to the methylated vectors, reduced
transcriptional activity of the minimal promoter nine-
fold compared to the activity obtained with the same
unmethylated reporter. When exon 1 is present in the
construct, the activity is reduced only two-fold. Moreover,
if we compare fold diﬀerence between the minimal
promoter activity and the minimal promoterþexon1 in
cassette methylation experiments, the diﬀerence is very
signiﬁcant when the plasmids are unmethylated; but when
the exon1 is methylated, there is almost no diﬀerence
(Figure 4C). These results suggested that the hypomethy-
lation of the region A (Figure 2), which contains three of
the four Sp1 binding sites, was permissive for low levels of
hTERT expression, comparable to those seen in vivo
(36,37), and that the methylation of the exon1 allowed the
transcriptional level to be likely the same than with the
minimal promoter only. These results also suggested that
the regions surrounding the region A in the minimal
promoter might be sites for a strong activator that might
have binding sites sensitive to methylation.
HeLa
Region A Region B
+1 (ATG) +100 −100 −200
Sp1 Sp1 Sp1 Sp1 E-box CTCF
SW480
42% Methylated 90% Methylated
40% Methylated 93% Methylated
BJ
3% Methylated 13% Methylated
HLF/hTERT
7% Methylated 23% Methylated
Figure 2. Genomic bisulﬁte sequencing of hTERT promoter and 50 exon region ( 200 to þ100 nucleotide bases around the ATG translational start
site). After PCR ampliﬁcation of bisulﬁte-modiﬁed DNA and cloning into pGEM-T vector, 12 clones of telomerase-positive cell lines (HeLa and
SW480), 8 clones of endogenously telomerase-negative cells (BJ and HLF/hTERT) and 8 clones from telomerase-positive tumor tissues (breast,
bladder and cervix) (Figure 2) were analyzed by sequencing. Clones of each are shown on the ﬁgure. Each square represents one CpG site. Filled
squares: methylated; open squares: unmethylated. Region A: in this region ( 80 to  165bp), multiple CpG sites were found to be unmethylated in
tumors tissues and cell lines. Region B: localization of the CTCF binding site within the ﬁrst exon of the hTERT gene, most of the CpG sites were
found to be methylated in telomerase-positive tumor tissues and cell lines. Percentages of methylated CG are indicated for regions A and B.
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The aim of the present study was to deﬁne more precisely
the role of CTCF and DNA methylation in transcriptional
regulation of the hTERT gene. CTCF binds preferentially
to GC-rich DNA regions, exerts an inhibitory eﬀect when
bound downstream of a transcriptional start site (39) and
may be released when its binding site is methylated (32).
In a previous study, we showed that CTCF binds to
GC-rich regions within exons 1 and 2 of the hTERT gene,
irrespective of the cell type or the promoter used. In the
hTERT CpG island, binding of CTCF might be inﬂuenced
by the methylation status of its sites. In the present study,
ChIP assays revealed that CTCF binds to the ﬁrst exon of
hTERT when the hTERT CpG island is not methylated.
In contrast, CTCF no longer binds its recognition
sequence when this site is methylated. Hypermethylation
of its binding site can therefore abolish CTCF repressor
activity. This was conﬁrmed by inducing demethylation
with 5-azadC, which allowed CTCF to bind to the ﬁrst
exon region and repress hTERT expression. Therefore,
the main role of hTERT methylation in tumor cells is
probably to prevent binding of the CTCF repressor and,
as a consequence, to allow transcription of the hTERT
gene.
The observation that 5-azadC treatment results
in hTERT gene repression was conﬁrmed by other
groups (33–35). Nevertheless, these results are apparently
in marked contrast to two other reports showing activa-
tion of hTERT following treatment of telomerase-negative
ALT cells upon 5-azadC (25,26). These seemingly
contrasting eﬀects might be explained as a result of the
balance between demethylation of the hTERT ﬁrst
exon region allowing binding of CTCF and, possibly,
demethylation of genes necessary for hTERT transcrip-
tion. Indeed, in luciferase reporter gene assays,
it was shown that the hTERT promoter is much less
active in ALT cells (e.g. U2-os) than in telomerase-positive
tumor cell lines (21). Further studies of ALT cells should
be undertaken to develop a better understanding of this
phenomenon.
Promoter methylation is an epigenetic process most
commonly associated with transcriptional repression.
Methylation of DNA helps to stabilize chromatin in an
inactive conﬁguration, thereby inhibiting gene expression
(28). As expected, our results clearly show that methyla-
tion of all the CpG sites within the hTERT promoter CpG
island resulted in complete transcriptional repression, in
spite of the inability of CTCF repressor to bind to the
hTERT gene. In this condition, hTERT does not provide
a real exception to the general model of gene silencing
by promoter methylation. However, even if hTERT is
generally hypermethylated in telomerase-positive tumor
cells (29), we showed in the present study that a region
between  165 to  80bp upstream of the translational
start site was hypomethylated in tumor tissues and cell
lines. This region contains three of the four Sp1 sites
present in the hTERT core promoter. We used cassette
methylation assay to demonstrate the importance of this
+1 (ATG) +100 −100 −200
Sp1 Sp1 Sp1 Sp1 E-box CTCF
Bladder cancer
Cervical cancer
Breast cancer
Region A Region B
0% Methylated 75% Methylated
55% Methylated 92% Methylated
45% Methylated 100% Methylated
Figure 2. Continued.
Nucleic Acids Research, 2007, Vol. 35, No. 4 1251region for the transcriptional activity of the hTERT
promoter. A recent study also showed that hTERT
transcription might require partial methylation of its
promoter (35). However, our data clearly indicate that
selective partial demethylation of 12 CpGs limited to the
small region upstream the transcription start site, deﬁned
as region A, signiﬁcantly activates hTERT promoter in
a reporter plasmid. Nevertheless, the activity of the
promoter in these conditions is signiﬁcantly lower than
the activity obtained with the unmethylated minimal
promoter. These results suggested that the regions
surrounding the minimal promoter region A might be
the target of transcriptional factors other than CTCF,
whose binding are sensitive to methylation. The low
expression level of the hTERT showed with this partial
demethylation of the core promoter corresponded
rather well to the level of hTERT expression observed
in vivo. Indeed, the hTERT mRNA levels detected in
telomerase-positive cell lines are very low, 0.2 to 6 copies
per cell (36,37). This is in stark contrast with
the high level of transcriptional activity obtained in
transient transfection of the hTERT core promoter in
B
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Figure 3. CTCF binding to the exogenous hTERT sequence after 5-azadC treatment. (A) Genomic bisulﬁte sequencing of hTERT promoter and ﬁrst
exon region ( 200 to þ100 nucleotide bases around the ATG translational start site). After PCR ampliﬁcation of bisulﬁte-modiﬁed DNA and
cloning into pGEM-T vector, 8 representative clones of HeLa and SW480 are shown. Each square represents one CpG site. Filled squares:
methylated; open squares: unmethylated. Region A and region B were represented for an easy comparison with Figure 2, and percentages of
methylated CG are indicated for regions A and B. (B) Binding of CTCF to the ﬁrst exon of hTERT in 5aza-dC cell lines was analyzed by ChIP assay
using anti-CTCF antibody. PCR coampliﬁcation of the test fragments (hTERT exon1 and H19) using as template DNA input fraction and DNA
recovered from immunoprecipitated fractions bound by the anti-CTCF antibody. (C) Quantitative reverse transcription-PCR analyses of hCTCF and
hTERT expression before and after 5azadC treatment. GAPDH expression is used to normalize samples.
1252 Nucleic Acids Research, 2007, Vol. 35, No. 4telomerase-positive cell lines, a level comparable to that
induced by strong SV40 early promoter (8).
Methylation cassette experiments shows that the expres-
sion levels of the construct with partially methylated
hTERT minimal promoter and methylated exon 1 in
transient transfection is very close to the levels of the
endogenous hTERT in human cancers showing similar
methylation pattern. The methylation of the exon1 of
hTERT seems to be suﬃcient to allow the transcription
from the minimal promoter, and does no more exert its
inhibitory eﬀect as seen in umethylated constructs.
Moreover, a CTCF site located at the beginning of exon
2 also plays an important role in the downregulation
of the constructs with unmethylated hTERT (18).
However, as previously mentioned, the presence of an
intron between the two CTCF sites complicates the
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Figure 4. Eﬀect of the hTERT promoter methylation on transcriptional activity. (A) Transcriptional activity of the hTERT minimal promoter was
assayed, with or without the presence of the hTERT exon 1 in a unmethylated CpG free plasmid. Methylated and unmethylated constructs were
transiently transfected in HeLa cells. The 100% activity is represented by the activity of unmethylated promoters. (B) Transcriptional activity of the
partially methylated hTERT minimal promoter was assayed in a unmethylated CpG free plasmid. Diﬀerent constructs were transiently transfected in
HeLa cells. The 100% activity is represented by the activity of unmethylated plasmid. (C) Fold diﬀerence activities between unmethylated and
partially methylated plasmids. The hTERT minimal promoter is taken as 1 in each case. Empty squares represent unmethylated CpG sites, and solid
squares represent methylated CpG sites. *P50.005 by Student’s t-test.
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Nevertheless, in our proposed model for the transcrip-
tional regulation of the hTERT gene (Figure 5), we took
the eﬀect of the two CTCF sites into account.
Although promoter methylation might be one of the
main mechanisms involved in hTERT regulation in tumor
tissues and cell lines (27,40,41), methylation-independent
mechanisms have also been identiﬁed (25,26,41–43).
In normal tissues, we observed that the hTERT gene was
not methylated in testis, a site where telomerase is highly
expressed (unpublished data). It is interesting to note that
expression of an hTERT transgene in mice remained high,
especially in testis, regardless of whether the transgene
comprised only an 8-kbp region of the hTERT promoter
or the entire hTERT gene promoter (21,44). According to
Horikawa et al., the use of the entire hTERT promoter in
mouse leads to a human-like pattern of hTERT expres-
sion, suggesting that speciﬁc regulatory sequences, rather
than mouse background, determines diﬀerences in hTERT
and mTERT expression. Together, these data suggest that
tissue-speciﬁc factors present in testis and in some tumor
cells could prevent binding of the CTCF repressor to the
ﬁrst two exons of hTERT and thus lead to hTERT
expression. According to previous data, the testis-speciﬁc
factor BORIS, a paralog of CTCF (45), might be a good
candidate, and further studies will be necessary to
investigate its potential role in the hTERT regulation.
In summary, hTERT expression is induced when the
hTERT CpG island is suﬃciently hypermethylated to
avoid binding of the CTCF repressor and when a small
part of the core promoter region is hypomethylated
to allow the transcription complex to be formed. Under
these conditions, additional regulators can come into
play to eﬀectively induce hTERT expression. Figure 5
illustrates the dual role of DNA methylation in the
transcriptional regulation of the telomerase hTERT gene.
The complexity of hTERT regulation might hamper the
development of anticancer therapies targeting telomerase
and calls for further studies.
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